Post-refractive IOL Outcomes With Clareon TruPlus

NCT07610226 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-05-27

No results posted yet for this study

Summary

This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.

Conditions

  • Cataract

Interventions

DEVICE

Clareon TruPlus

Clareon TruPlus

Sponsors & Collaborators

  • Sengi

    collaborator INDUSTRY
  • Laser Defined Vision

    lead OTHER

Principal Investigators

  • Karl Stonecipher, MD · Physicians Protocol

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-23
Primary Completion
2027-06-23
Completion
2027-06-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07610226 on ClinicalTrials.gov